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Amyloid-beta transporter expression at the
blood-CSF barrier is age-dependent
Crissey L Pascale1, Miles C Miller1, Catherine Chiu1, Matthew Boylan1, Ilias N Caralopoulos1, Liliana Gonzalez2,
Conrad E Johanson1 and Gerald D Silverberg1*
Abstract
Background: Age is the major risk factor for many neurodegenerative diseases, including Alzheimer’s disease (AD).
There is an accumulation of amyloid-beta peptides (Ab) in both the AD brain and the normal aging brain.
Clearance of Ab from the brain occurs via active transport at the blood-brain barrier (BBB) and blood-cerebrospinal
fluid barrier (BCSFB). With increasing age, the expression of the Ab efflux transporters is decreased and the Ab
influx transporter expression is increased at the BBB, adding to the amyloid burden in the brain. Expression of the
Ab transporters at the choroid plexus (CP) epithelium as a function of aging was the subject of this study.
Methods: This project investigated the changes in expression of the Ab transporters, the low density lipoprotein
receptor-related protein-1 (LRP-1), P-glycoprotein (P-gp), LRP-2 (megalin) and the receptor for advanced glycation
end-products (RAGE) at the BCSFB in Brown-Norway/Fischer rats at ages 3, 6, 9, 12, 20, 30 and 36 months, using
real time RT-PCR to measure transporter mRNA expression, and immunohistochemistry (IHC) to measure
transporter protein in isolated rat CP.
Results: There was an increase in the transcription of the Ab efflux transporters, LRP-1 and P-gp, no change in
RAGE expression and a decrease in LRP-2, the CP epithelium influx transporter, at the BCSFB with aging. Decreased
Ab42 concentration in the CP, as measured by quantitative IHC, was associated with these Ab transporter
alterations.
Conclusions: Age-dependent alterations in the CP Ab transporters are associated with a decrease in Ab42
accumulation in the CP, and are reciprocal to the changes seen in these transporters at the BBB, suggesting a
possible compensatory role for the BCSFB in Ab clearance in aging.
Keywords: aging, amyloid-beta, transport, choroid plexus, blood-CSF-barrier, LRP-1, LRP -2, P-gp, RAGE
Background
Advancing age is a major risk factor for many neurode-
generative disorders, and the major risk factor for Alz-
heimer’s disease (AD), a disease characterized by
progressive memory and cognitive loss [1]. The most
accepted hypothesis for the mechanism of brain injury
in AD is the “amyloid cascade,” comprising amyloid
accumulation in the brain, the formation of toxic oligo-
meric and intermediate forms of amyloid-beta peptides
(Ab), amyloid plaques, inflammation and the induction
of neurofibrillary tangles [2-4]. There is accumulation of
Ab in both the normal aging brain and the AD brain,
thought to be related to defective Ab clearance rather
than increased Ab production [4-7]. This has recently
been shown to be the case in AD [8]. Clearance of this
peptide from the brain occurs via active transport at the
interfaces separating the central nervous system from
the peripheral circulation.
We have recently shown that the blood-brain barrier
(BBB) undergoes significant alterations in Ab transpor-
ter expression with aging [5,9]. These changes likely
lead to a decrease in amyloid efflux from the brain and
an increase in amyloid influx, associated with an
increasing CNS amyloid burden. Similar Ab transporter
expression changes have been shown in AD brains
[10-12]. The blood-CSF barrier (BCSFB) also undergoes
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age-related changes, and it is important to study the
effects of aging on this alternative pathway for transpor-
ter-mediated amyloid clearance [13,14].
BBB Ab clearance is an energy-dependent (active) pro-
cess via specific transporter proteins [15,16]. The recep-
tors for Ab at the BBB bind Ab directly, or bind to one
of its carrier proteins, and transport it across the
endothelial cell. The low density lipoprotein receptor-
related protein 1 (LRP-1) and P-glycoprotein (P-gp)
have been implicated in Ab efflux [17,18]. LRP-1 is
located on the abluminal endothelial cell membrane,
whereas P-gp is located on the luminal (blood-facing)
surface. The receptor for advanced glycation end pro-
ducts (RAGE), also located on the luminal side of the
endothelium, has been linked to Ab influx [19].
It has been hypothesized that AD is on a continuum
with normal aging, although the exact causes for the
transition from aging to AD are not yet fully understood
[14,20]. In addition to the reduction in clearance of Ab
across the BBB with increased age, there is also a
decline in its clearance via CSF bulk flow [21]. We have
also demonstrated that interfering with the bulk flow of
CSF by induced hydrocephalus causes amyloid to accu-
mulate in the aged rat brain [22]. An increase in ventri-
cular size and a decrease in CSF production and
turnover have been demonstrated in senescence, AD
and hydrocephalus of the elderly [21,23,24]. Decreased
CSF turnover has been postulated to be an important
risk factor for AD [7,14].
Solute transport at the BCSFB occurs across the choroid
plexus (CP) epithelium [25,26]. Although CSF bulk flow
decreases with age and AD, active transport of solutes,
such as Ab, across the CP may not. The same Ab trans-
porters located on the endothelial cells of the BBB are also
found at the BCSFB, e.g., LRP-1, P-gp and RAGE, as well
as another receptor known to transport Ab from the CSF
into the CP epithelium, the low density lipoprotein recep-
tor-related protein 2 (LRP-2). Although the LRP receptors
may transport solutes bi-directionally, there is evidence
that LRP-1 and P-gp are Ab efflux transporters and LRP-2
primarily transports Ab from CSF into the CP epithelium
[27-30]. Herein, we report the changes in mRNA expres-
sion and receptor protein density of these Ab transporters
on the CP epithelium as a function of age. Expression of
receptor mRNA was measured by real time reverse tran-
scription-polymerase chain reaction (RT-PCR). Immuno-
histochemistry (IHC) was used for protein sub-cellular
localization and semi-quantitative measurements of recep-
tor expression. IHC was also used to measure Ab40 and
Ab42 accumulation in CP with advancing age. Interest-
ingly, the overall changes in expression that we found at
the BCSFB were reciprocal to those seen at the BBB, and
different from AD CP.
Methods
Tissue collection
All experiments were approved by the Rhode Island
Hospital Institutional animal care and use committee.
Male Brown-Norway/Fischer (B-N/F) rats (n = 254)
were purchased from the National Institute on Aging at
ages 3, 6, 9, 12, 20, 30, and 36 mo. B-N/F rats are not
as susceptible to cancer as the more inbred species and
can live in excess of 36 mo. Under a surgical plane of
anesthesia, induced by intraperitoneal injection of pen-
tobarbital (50 mg/kg), the animals were perfused with
0.9 M phosphate buffered saline (PBS), pH 7.4, at 4°C
via the left ventricle of the heart, using a peristaltic
pump (Harvard Apparatus, Holliston, MA, USA). The
two lateral ventricle CPs were then dissected out under
a microscope and placed in a microcentrifuge tube con-
taining either 4% paraformaldehyde (PFA) for fixation
prior to IHC, or RNAlater (Ambion, Austin, TX, USA)
to limit degradation by endonucleases before RT-PCR
analysis. Eight CPs from four rats were pooled for each
sample used downstream for PCR, and two CPs from
one rat were used for each IHC sample. For PCR, n = 8
(32 rats) were tested for each age group and for IHC n
= 5 (five rats) were used for each age group.
Real time RT-PCR
Samples stored in RNAlater were allowed to thaw and
were rinsed with nuclease-free water before homogeniz-
ing in the lysis buffer provided in the Qiagen RNeasy kit
(Qiagen, Valencia, CA, USA). This kit was used, per the
manufacturer’s instructions, to extract the RNA. RNA
concentrations were measured by a NanoDrop 1000
spectrophotometer (ThermoFisher Scientific, Wilming-
ton, DE, USA) and stored at -80°C until further use. 1
μg of RNA was used with the Omniscript Reverse Tran-
scription kit (Qiagen) to synthesize 20 μL of cDNA. For-
ward (F) and reverse (R) primers for each gene of
interest were designed using Primer Premier software
(PREMIER Biosoft International, Palo Alto, CA, USA).
The primers used were as follows (written from 5’ to 3’):
LRP-1 F CAAGATGTATGAAGGTGGAGAGC, LRP-1 R
ACTGGGTTGGTGAAGTTGGTAG (TA = 62°); LRP-2 F
GCAGAGATGGACAGTGAGGT, LRP-2 R GCTGG
CGAGGCTATACG (TA = 62°); P-gp F GGACAAAGC-
CAGGGAAGG, P-gp R GGTGGGTGCCGTGCTC (TA =
60°); RAGE F GCAGGCTCTGTGGATGGG, RAGE R
GAGTCTGGGTTGTCGTTTTCG (TA = 62°); and bACT
F AAAGACCTCTATGCCAACACAGT, bACT R GAGC-
CACCAATCCACACAG (TA = 60°). In each 50 μL real
time RT-PCR reaction using SYBR-ER master mix (Invi-
trogen, Carlsbad, CA, USA), 10 mM primers and 1 μL
cDNA were implemented. Reactions were run in a Bio-
Rad iCycler (Bio-Rad, Hercules, CA, USA) using
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Invitrogen’s suggested protocol. Annealing temperatures
(TA) varied and were specific for each primer set. Stan-
dards corresponding to each gene were generated by
first amplifying template DNA (bACT: rat cerebral cor-
tex; LRP-1 and RAGE: rat lung; LRP-2: rat kidney; P-gp:
rat liver) using a set of gene-specific primers in eight
100 μL RT-PCR reactions. An equal volume of phenol:
chloroform was then added to the combined product
and mixed vigorously for 15 sec. After sitting on ice for
10 min, the mixture was centrifuged for 20 min on max-
imum speed at 4°C. The aqueous phase was carefully
removed to another microcentrifuge tube where 1/10
volume of sodium acetate was added and mixed. An
equal volume of 100% ice cold ethanol was added and
allowed to sit overnight in a -20°C freezer. The DNA
was pelleted, resuspended in 20 μL Tris EDTA buffer,
and run on a 2.5% low melting temperature agarose gel
(Fisher Scientific, Fairlawn, NJ, USA) in Tris Borate
EDTA buffer for 1.5 h. Due to the intercalating dye,
Gelred (Biotium, Hayward, CA, USA), that was added to
the gel pre-run, the DNA band was visualized under UV
light and was then extracted. The DNA was purified
from each gel slice using Promega Wizard columns
(Promega, Madison, WI, USA). The concentration of
DNA was determined using a spectrophotometer (Ther-
moFisher Scientific) and a serial dilution for each gene
of interest was created (102 to 106 copies per μL). Stan-
dards for a particular gene were run in each reaction
corresponding to that gene. Both standards and samples
were run in duplicate, and all runs contained an inter-
run calibrator to account for any differences between
runs. A melt curve was generated for every reaction and
viewed to ensure only the gene of interest was being
amplified. All data were normalized to the housekeeping
gene, b-actin (bACT), before statistical analysis was
performed.
Immunohistochemistry
Specimens stored in PFA were processed, embedded in
paraffin, and sectioned at a thickness of 10 μm. After
deparaffinization and rehydration, tissue sections were
treated with hot (85°C) 10 mM citrate buffer, pH 6, for
20 min. Sections were washed with distilled water and
quenched with a peroxidase-blocking reagent (Dako,
Carpinteria, CA, USA) for 10 min at room temperature
to eliminate endogenous peroxidase activity. After wash-
ing in 0.05 M Tris-buffered saline with 0.05% Tween-20
(TBST), pH 7.6, sections were incubated overnight at 4°
C with their appropriate primary antibody: rabbit poly-
clonal to Ab40 (Linaris, Wertheim-Bettingen, Germany;
Cat. # PAK6012, diluted 1:100), rabbit polyclonal to
Ab42 (Linaris, # PAK6023, diluted 1:200), rabbit poly-
clonal to LRP-1 (Orbigen, San Diego, CA, USA; # PAB-
10774, diluted 1:1000), rabbit polyclonal to LRP-2
(Orbigen, # PAB-10775, diluted 1:2000), mouse mono-
clonal to P-glycoprotein (Abcam, Cambridge, MA, USA;
# ab3364, diluted 1:100), or goat polyclonal to RAGE
(Abcam, # ab7764, diluted 1:400). After washing the sec-
tions in TBST, a horseradish peroxidase (HRP)-labeled
polymer conjugated with secondary antibodies: anti-
mouse (Dako) or anti-rabbit (Dako), was applied for 30
min at room temperature, in accordance with the EnVi-
sion+ System for IHC staining. For RAGE only, the sec-
tions were instead subjected to a modified ABC
technique using the Vectastain Elite ABC Goat Peroxi-
dase system (Vector Laboratories, Burlingame, CA,
USA). All tissue sections were washed in TBST and
stained using 3,3-diaminobenzidine (Dako) as the chro-
mogen. Following development, P-gp sections were
counterstained for 30 sec with a 1% light green SF yel-
lowish solution (Sigma, St. Louis, MO, USA). Sections
were dehydrated through a series of graded alcohols and
xylene, and then coverslipped and sealed using Cytoseal
XYL, a xylene-based mounting medium (Richard-Allan
Scientific, Kalamazoo, MI, USA). Primary antibody
omission controls were run alongside the other samples
to check for non-specific binding due to the secondary
antibody, along with positive control tissue (human hip-
pocampus with Braak and Braak Stage VI AD pathology,
human lung, and human kidney).
Image Analysis
All IHC slides were converted to digital images using
Aperio ScanScope (Aperio Technologies, Vista, CA,
USA) as 8-bit acquisitions of color. Image analysis was
completed in Image J (v. 1.43 u, NIH, Bethesda, MD,
USA). For all stains except for P-gp, stained tissue was
selected on the Red Channel based on a specific thresh-
old value, and the ‘Mean Gray Value’ was measured
from the selection. This value renders the average stain
intensity as grayscale units (GU) for all thresholded pix-
els. Quantification of P-gp immunoreactivity was deter-
mined by the pixel ratio of stained tissue area to total
tissue area [% region of interest (ROI)]. IHC images
were taken for six age groups: 3, 6, 12, 20, 30, and 36
mo. Our semi-quantitative IHC methods have been
shown to correlate very closely with western blot mea-
surements of Ab receptor protein at the BBB [5,9].
Statistical methods
For the RT-PCR analysis, Bio-Rad iQ5 Optical System
software (Bio-Rad, Hercules, CA, USA) using the ΔΔCT
method to calculate the normalized expression of each
gene for each sample was employed. Natural logarithm
transformations of the data were used to correct for
non-normality and inequality of variances, which was
then confirmed by Shapiro-Wilk’s and Levene’s tests.
For both the RT-PCR and the IHC analyses a single-
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factor ANOVA followed by Tukey’s pairwise compari-
sons were used to analyze the data. The confidence lim-
its (CL) for differences in the means (pairwise
comparisons) were calculated for the mean of higher -
mean of lower age group. All statistical analyses were
conducted using the SAS software (V. 9.2, SAS Institute,
Cary, NC, USA).
Results
LRP-1
The expression of the Ab efflux transporter LRP-1 at
the messenger RNA (mRNA) level as a function of
aging was measured by real time quantitative RT-PCR
at 3, 6, 9, 12, 20, 30, and 36 mo. There was a mild
decrease in LRP-1 expression from 3 to 9 mo, followed
by a significant increase to 30 mo and then a mild
decrease again to 36 mo (Figure 1A). A one-way
ANOVA showed an effect of age for the seven tested
age groups at the p < 0.05 level [F(6, 49) = 2.33, p =
0.047]. Tukey’s pairwise comparisons revealed a
significant difference in the mean natural log-trans-
formed normalized expression of LRP-1 between 9 and
30 mo [difference between means (DMB) = 0.5975; 95%
confidence limits (CL) (0.0122, 1.1828)]. However, the 3,
6, 12, 20, and 36 mo groups did not significantly differ
from each other, or from the 9 and 30 mo groups. From
3 to 36 mo, therefore, CP LRP-1 expression was either
stable or increased with age.
Semi-quantitative image analysis of the IHC for the
LRP-1 protein receptor revealed a similar expression
change with aging (Figure 1B). The mean staining inten-
sity was measured in grayscale units (GU). LRP-1
expression was different at the p < 0.05 level for the six
different age groups [F(5,24) = 5.27, p = 0.0021]. Tukey’s
pairwise comparison showed a significant increase in
mean staining intensity (GU) between 3 and 20 mo
[DBM = 8.633; 95% CL (2.052, 15.215)] and 3 and 30
mo [DBM = 8.105; 95% CL (1.524, 14.687)]. There was
a significant decrease from 20 to 36 mo, [DBM =
-6.707, 95% CL (-13.288, -0.125)]. LRP-1 staining
Figure 1 LRP-1 expression at the CP epithelium with age. (A) Graph of the log-transformed normalized expression of LRP-1 with age, n = 8
for each age group tested (4 rats, 8 CPs pooled for each “n”, 32 rats for an n = 8). One-way ANOVA revealed a significant increase in LRP-1
expression (p = 0.047). Significance was reached between 9 and 30 mo 95% confidence limits (0.0122, 1.1828). Error bars represent 95%
confidence intervals for the means. (B) Semi-quantitative IHC for LRP-1 expression in grayscale units (GU). Mean staining intensity was
significantly different (p <0.05) for the six age groups, n = 5 for each age group (5 rats, 2 CPs for each sample). (C) IHC of LRP-1 expression at 3
mo (top), 30 mo (center) and 36 mo (bottom) old rats. Staining is localized to the apical membrane (arrows).
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appeared to be most intense along the apical membrane
of the CP epithelial cell (Figure 1C).
LRP-2
The expression of the Ab CP influx transporter LRP-2
at the mRNA level with age was also measured by RT-
PCR at the same time points as LRP-1. There was a
decrease in LRP-2 expression from 3 to 36 mo (Figure
2A). One-way ANOVA showed an effect of age for the
seven age groups at the p < 0.05 level [F(6, 49) = 4.93, p
= 0.0005]. Tukey’s pairwise comparisons revealed signifi-
cant differences in the mean natural log-transformed
normalized expression of LRP-2 between 3 and 9 mo
[DBM = 0.4323; 95% CL (-0.8340, -0.0305)], 3 and 12
mo [DBM = 0.5061; 95% CL (-0.9078, -0.1044)], 3 and
20 mo [DBM = 0.6270; 95% CL (-1.0287, -0.2253)], 3
and 30 mo [DBM = 0.5183; 95% CL (-0.9201, -0.1166)]
and 3 and 36 mo [DBM = 0.4887; 95% CL (-0.8904,-
0.0869)]. The results show a continuous decrease in the
expression of LRP-2 at the CP epithelium after 3 mo of
age.
Semi-quantitative image analysis of the IHC for the
LRP-2 protein receptor showed similar results (Figure
2B). The mean staining intensity was different at the p <
0.05 level for the different age groups [F(5,24) = 3.47, p
= 0.0168]. Tukey’s pairwise comparison showed a signif-
icant decrease in mean staining intensity between 12
and 36 mo [DBM = -7.924; 95% CL (-14.199, -1.729)].
There also appeared to be some localization of the LRP-
2 staining to the apical membrane of the CP epithelium,
but subapical staining was also evident (Figure 2C).
P-gp
The expression of P-gp as a function of age, measured
by RT-PCR, showed an increase from 3 to 36 mo (Fig-
ure 3A). A one-way ANOVA showed an effect of age
for the seven age groups at the p <0.05 level [F(6, 49) =
4.90, p = 0.0005]. Tukey’s pairwise comparisons indi-
cated a significant increase in the mean natural log-
transformed normalized expression between 3 and 30
mo [DBM = 0.5759; 95% CL (0.0603, 1.0915)], 6 and 30
mo [DBM = 0.7134; 95% CL (0.1978, 1.2290)], 9 and 30
months [DBM = 0.5454; 95% CL (0.0298, 1.0610)], 12
and 30 mo [DBM = 0.6153; 95% CL (0.0997, 1.1309)],
and between 6 and 36 mo [DBM = 0.5620; 95% CL
(0.0464, 1.0776)]. These results indicate that P-gp
Figure 2 Expression of LRP-2 at the CP with age. (A) Graph of the log-transformed normalized expression of LRP-2 with respect to age, n = 8
per age group. One-way ANOVA revealed a significant decrease (p = 0.0005) with age on LRP-2 expression. Significance was reached between 3
and 9, 12, 20, 30, and 36 mo. Error bars represent 95% confidence intervals for the means. (B) Semi-quantitative IHC for LRP-2 expression in
grayscale units (GU). Mean staining intensity was significantly decreased (p <0.05) for the age groups, n = 5 per age group. (C) IHC of LRP-2
expression at 3 mo (top), 20 mo (center), and 36 mo (bottom) old rats. Staining is localized to the apical membrane (arrows), and is also seen
subapically.
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expression in the CP epithelium increases with age at
the mRNA level. This effect becomes significant at 30
mo. It should be noted that the increase at 36 mo was
only significant when compared to the 6 mo age group.
Due to the punctate nature of the P-gp IHC staining,
semi-quantitative image analysis of the IHC for the
expression of P-gp (Figure 3B) compared the ratio of
stained tissue area (pixels) to total tissue area (pixels)
rather than mean stain intensity. No significant differ-
ence in this ratio was found for the different age groups
at the p < 0.05 level, though there was a general trend
towards increased expression with age. P-gp staining
was mainly localized to the basolateral CP epithelial
membrane, though it was occasionally seen at the apical
membrane as well (Figure 3C).
RAGE
The expression of RAGE with respect to age was also
measured by RT-PCR. One-way ANOVA assessed the
effect of age on the mean natural log-transformed nor-
malized expression of RAGE at 3, 6, 9, 12, 20, 30 and 36
mo. There was no significant effect of age on the
expression of RAGE at the p <0.05 level [F(6, 49) =
0.88, p = 0.52]. Image analysis for the IHC performed
for the RAGE protein confirmed that no significant dif-
ferences between any of the age groups were present (p
= 0.4041). RAGE staining did not appear to localize to
CP membranes but rather was cytosolic (PCR and IHC
data not shown).
Ab40/42
IHC for Ab40 and Ab42 deposition was also analyzed
semi-quantitatively. The mean staining intensity was
not significantly different at the p < 0.05 level for
Ab40, p = 0.3384, (data not shown), but there was a
significant decrease with age [F(5, 23) = 6.40, p =
0.0007] for Ab42 (Figure 4A). Tukey’s pairwise com-
parison showed a significant decrease in mean staining
Figure 3 Age-related P-gp expression at the CP. (A) Graph of the log-transformed normalized expression of P-gp with respect to age, n = 8
for each age group. One-way ANOVA revealed a significant increase (p = 0.0005) with age on P-gp expression. Significance was reached
between 30 mo and 3, 6, 9, and 12 mo, and between 36 mo and 6 mo. Error bars represent 95% confidence intervals for the means. (B) Semi-
quantitative IHC for P-gp expression. Stain area to tissue area ratio was not significantly different (p > 0.05) for the six age groups, n = 5 per age
group. (C) IHC of P-gp expression at 3 mo (top), 20 mo (center), and 36 mo (bottom) old rats. Majority of staining is localized to the basolateral
membrane (arrows), though on occasion it is seen along the apical membrane (asterisk).
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intensity for Ab42 between 3 and 36 mo [DBM =
-7.606; 95% CL (-12.337, -2.874)], 6 and 36 mo [DBM
= -5.567; 95% CL (-10.299, -0.835)], 12 and 36 mo
[DBM = -6.839; 95% CL (11.570, -2.170)], and 30 and
36 mo [DBM = -5.200; 95% CL (-10.219, -0.812)]. Age
decreases Ab42 deposition in the CP epithelium of the
B-N/F rat. Ab42 staining is granular and primarily
cytosolic, though it was also found along the apical CP
membrane (Figure 4B).
Figure 5 summarizes the CP Ab transporters, as we
believe they function from the data presented. The fig-
ure compares qualitatively the direction and expression
of the transporters at three months (A) and after 20
months (B).
Discussion
Increased amyloid burden in the AD brain is neurotoxic
and leads to neuritic plaque formation, chronic
Figure 4 Ab42 concentration in the CP epithelium with age. (A) Semi-quantitative IHC for Ab42 deposition. Mean staining intensity in
grayscale units (GU) was significantly decreased (p < 0.05) for the age groups, n = 5 per age group. (B) IHC of Ab42 at 3 mo (left), 20 mo
(center), and 36 mo (right) old rats. Staining is granular and primarily cytosolic (asterisks), though also found along the apical membrane (arrows).
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inflammation and neuronal death [2,31]. Amyloid accu-
mulation is related to a decrease in Ab clearance
[4,7,8,20]. It has been postulated that the lack of clear-
ance from the brain via transporters at the BBB is the
major mechanism behind Ab buildup in senescence and
in AD [5,9,14,16]. We now show that Ab clearance at
the BCSFB may be enhanced with age, reciprocal to Ab
transporter alterations at the BBB.
As noted, most Ab clearance pathways become com-
promised in the aged brain. Aside from the alterations
in BBB transporter expression, and the attenuation of
CSF bulk flow, enzymatic degradation of Ab by insulin-
degrading enzyme and/or neprilysin may also be dimin-
ished [32]. The CP epithelial cell surface area is enlarged
by the basal labyrinth interdigitations and the apical
microvilli, but is still less than the BBB endothelium.
However, the contribution to Ab clearance by the CP is
not insubstantial, owing in part to the high levels of Ab
degrading enzymes present [33]. Indeed, with the clear-
ance deficits that occur at the BBB, and the decrease in
CSF turnover that occurs with age, the role of Ab trans-
port and degradation at the BCSFB becomes increas-
ingly more prominent. Between nine and 12 months of
age in the B-N/F rat aging model, whole brain Ab rises
rapidly [5]. At 12 months of age CP Ab42 begins to
decrease as P-gp expression starts to increase and LRP-2
expression is decreasing. LRP-1 expression remains
stable until 20 months and then increases.
Central to the functioning of the BCSFB is the CP, the
organ responsible for monitoring both plasma and CSF
concentrations of many solutes, e.g., vitamins, hor-
mones, harmful metabolites and immune cells, and reg-
ulating solute concentrations [26,34,35]. The CP likely
influences neurogenesis in the damaged brain through
the CSF transport of mitogenic growth factors to neuro-
genic niches near the ventricular wall [36]. In aging and
in AD there is a decrease in the production and turn-
over of CSF allowing toxic metabolites, such as Ab,
more retention time in the brain [7,21,23]. At the same
time there is a flattening of the CP epithelium, thicken-
ing of the basement membrane, and overall atrophy of
the CP cells [37,38]. Therefore, it is of major interest
that, despite these dystrophic CP changes, our aging rat
CP data shows an increase in expression of the Ab
efflux transporters LRP-1 and P-gp, and either no
change (RAGE) or a decrease in the expression of the
CP influx transporter (LRP-2) in association with a sig-
nificant decrease in CP Ab42 concentration, as mea-
sured by IHC. This observation may have a significant
bearing on the transition that occurs between normal
aging and AD.
Ab concentration is increased in the CP of AD brains,
and the expression of the CP Ab transporters is altered
to decrease Ab efflux and/or degradation [39,40]. Ab is
shuttled bi-directionally across the BCSFB, and the net
flux and rate of Ab transport is determined by the com-
bined expression and activities of the CP Ab transpor-
ters [41]. The amount of data available at present for
the cell membrane localization of the amyloid transpor-
ters, and the direction and activity of transport is small.
Hence much more work needs to be done in these
areas. However, the Ab efflux transporter expression
increase and the decrease in CP Ab42 suggest a net
increase in Ab efflux at the BCSFB in the aging rat.
Loss of this Ab clearance route may be a determining
factor in the increase in CP Ab seen in AD. Ab accumu-
lation in the CP increases apoptosis and interferes with
oxidative phosphorylation, disrupting the BCSFB and
likely further decreasing CSF turnover [40]. Ab therefore
contributes progressively to an inability to clear itself.
The low density lipoprotein receptor (LDLR) family is
an ancient and highly conserved family of receptors
Figure 5 Diagrams of the direction and expression of the Ab
transporters at the BCSFB. (A) Diagram to show the direction and
relative expression of LRP-1, P-gp and LRP-2 at three months of age
in the BN/F rat. (B) Diagram of the relative expression of the three
transporters after 20 months. Note that LRP-1 and P-gp expression
increase, whereas LRP-2 expression decreases with age.
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with endocytic and cell signaling functions. These recep-
tors bind a wide range of ligands, including Ab [42,43],
and LRP-1 has been linked to AD [18,44,45]. LRP-1 has
been localized to neurons, glial cells, the endothelial
cells of the BBB and the epithelial cells of the BCSFB. It
has been shown to bind both Ab40 and Ab42, alone, or
conjugated to one of their carrier proteins, and remove
them from the extracellular space. Once bound, LRP-1
can target Ab for cellular degradation, or facilitate its
transcytosis [46]. A fully functional soluble form, sLRP-
1, can also be found in the plasma, brain ISF and CSF
[47]. At the BBB, LRP-1 transports Ab out of the brain.
BBB LRP-1 expression has been shown to decrease sig-
nificantly in aging and in AD [9,10]. At the BCSFB,
LRP-1 actively transports Ab out of the CSF [27].
The present study demonstrates that the mRNA
expression and protein levels of LRP-1 increase in CP,
and an increase in sLRP-1 in the CSF with advancing
age has been reported [47]. It has been shown that
Ab42 can increase the CSF shedding of membrane-
bound LRP-1 as sLRP-1 [47]. An increase of sLRP-1
would create an Ab sink in the CSF, allowing Ab to
accumulate in the CSF by binding to sLRP-1. When
bound, Ab would be inhibited from self-aggregation.
The bound Ab would be transferred to the systemic cir-
culation for degradation.
LRP-2 is another member of the LDLR family known
to transport Ab at the BCSFB. LRP-2 is expressed on
capillary endothelium and CP epithelium, though its
expression is 17-fold higher in CP epithelium [48]. It
has been demonstrated that LRP-2 binds to Ab40 when
it is conjugated to apolipoprotein J (ApoJ) and trans-
ports it into the CP epithelial cell from the CSF [29].
LRP-2 also transports solutes from blood into the CP
epithelium, and from there into the CSF and brain.
LRP-2 has not only been implicated in Ab transport,
but also the transport of leptin and insulin-like growth
factor 1 (IGF-1) from the peripheral circulation, across
the CP, and into the brain [49,50]. Transport of Ab into
the CP cells may keep it from forming aggregates within
the cell, or it could facilitate its degradation by endoly-
sosomes. At the BBB, LRP-2 acts in a manner similar to
RAGE, transporting Ab out of the blood and into brain.
However its high saturability with ApoJ not bound to
Ab may restrict its role in Ab influx transport at the
BBB [51]. LRP-2 actions at the BCSFB are less clear. It
appears to transport solutes into the CP epithelium
from both blood and CSF, and either degrades them
within the cell or transports certain ones into the brain
via the CSF. The present study finds the transcription of
LRP-2 in CP to be significantly down-regulated with
age, and its protein levels also decreased. Other groups
have shown a similar decrease in the protein levels of
LRP-2 at the BCSFB with age and AD [39,49,50]. The
decline of LRP-2 expression with age might restrict the
passage of Ab into the CP epithelium; however, this
could also restrict certain neuroprotectants like IGF-1
transported by LRP-2 into the CSF and brain. It has
been suggested that this lack of neuroprotectant trans-
port leads to cognitive decline [49].
P-gp is a member of the ATP binding cassette super-
family. This is another highly promiscuous receptor
which exhibits a high degree of cross-reactivity with a
number of unrelated substances. As an efflux transpor-
ter it acts to protect the brain at the BBB by pumping
xenobiotics out of the brain [28,52]. It has been demon-
strated that P-gp is decreased at the BBB late in aging
[9,17]. Its role at the BCSFB, however, is poorly under-
stood. In this study, P-gp transcript expression signifi-
cantly increased with advancing age. IHC localized P-gp
primarily to the basolateral membrane of the epithelial
cells, suggesting solute transport from the CP into the
peripheral circulation. Other studies have not shown
this basolateral localization of P-gp. Rao et al. (1999)
concluded that P-gp was located sub-apically from stain-
ing patterns and functional tests [53]. Age seems to be
the most likely explanation for this discrepancy between
studies. In that study, neonatal CPs and cell cultures
were used, rather than adult and aged rats as in the pre-
sent study. It is possible that cell signaling directs P-gp
to different membrane sites at various stages of life.
Another endocytic receptor and transporter of Ab is
RAGE. It is a member of the immunoglobulin superfam-
ily and its ligands include many diverse proteins which
have undergone post-translational modifications [54]. As
part of the innate immunity of the brain, the interaction
between RAGE and its ligands can stimulate an inflam-
matory response and lead to oxidative stress within cells
[55]. RAGE-Ab interaction at the BBB has also been
shown to lead to T-cell infiltration of the brain [56]. At
the BBB, RAGE expression increases with advancing age
and AD, increasing Ab influx [5,12]. Few studies have
explored the role of RAGE at the BCSFB. One study
showed that RAGE increases in the CP after diabetic
ketoacidosis, interestingly, without an increase in amy-
loid [30]. Both the transcript expression and the protein
analysis in our study did not show any significant
change with increased age, nor did the IHC demonstrate
clearly the sub-cellular location of RAGE. It is unclear at
this point what the role of RAGE is at the BCSFB in
relation to Ab transport.
Our data show that the Ab efflux transporter up-regu-
lation at the BCSFB occurs in a manner opposite to that
in the BBB, suggesting a possible compensatory role for
the CP in eliminating amyloid from the CSF, CP and
brain in aging. Although more confirmatory studies
need to be done to be certain of the localization and
direction of transport of the LRP receptors on the CP, it
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is important to note that Ab42 was shown to signifi-
cantly decrease in the CP with increased age as one
would predict from the transporter expressions and
directions that we have reported. This differs from the
findings in the CPs of AD patients [39,40]. Other studies
have also found differences between aging and AD in
the CSF levels of sLRPs [47] and transthyretin, known
to bind Ab in the CSF and impede amyloid fibrillogen-
esis [57]. Both of these proteins are decreased in AD
compared to age-matched controls. The changes in Ab
transporter expression at the BBB between aging and
AD are in the same direction, though more severe in
AD. The differences between aging and AD at the CP
and BCSFB may be where the normal aging brain and
AD brain differ the most. These differences, and the sig-
naling mechanisms behind them, may provide some
insight into the complex relationship between aging and
AD.
Conclusions
Aging alters the expression of the amyloid transporter
genes at the BCSFB in a way that may facilitate amyloid
clearance across the CP epithelium, i.e., there is an
increase in the expression of the Ab efflux transporters
LRP-1 and P-gp, whereas the CP Ab influx transporter
LRP-2 is decreased. The changes in expression of the
Ab transporter genes at the BCSFB are opposite to
those seen at the BBB in aging, and may be a compensa-
tory mechanism to aid the failing BBB Ab clearance
pathways. Eventual failure of this compensatory
mechanism may have implications for Ab accumulation
in both normal aging and in AD.
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